CTP Imaging of Lung Cancer

Non Small Cell Lung Cancer Clinical Trial

— CTPLC  

Official title:

CTP (Computed Tomography Perfusion) Imaging of Lung Cancer

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01823094
• Other study ID #: 393991
• Status: Completed
• Phase: N/A
• First received: March 22, 2013
• Last updated: January 22, 2016
• Start date: March 2013
• Est. completion date: June 2015

Study information

• Verified date: January 2016
• Source: University of California, Davis
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Institutional Review Board
• Study type: Observational

Clinical Trial Summary

Investigators hope to learn more about how to use computed tomography (CT) scans to measure blood flow in lung tumors and how it may change in response to treatment. This measurement technique is called computed tomography perfusion (CTP). CT scanners use X-rays to produce 3-dimensional images of the body.

Currently, doctors determine the response to treatment by measuring the size of the tumor. Investigators are trying to find out if measuring the blood flow in the tumor is equal to or better than measuring the size of the tumor.

Description:

This is an experimental study of CT perfusion (CTP) imaging in subjects with non-small cell lung cancer. The objectives of this study are to demonstrate the feasibility of CT blood flow measurements in lung cancer, to develop a foundation for the use of CT blood flow measurements in lung cancer to assess the response to treatment, and to develop an optimized CTP imaging protocol for evaluating blood flow in solid body tumors. In this study, tumor blood flow will be evaluated at baseline and follow-up routine CT examinations of patients with non-small cell lung cancer, and the response of tumor blood flow will be recorded as a secondary endpoint. This research study will entail two study visits - one required and one optional - which will coincide with regularly scheduled standard of care CT scans.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 14
• Est. completion date: June 2015
• Est. primary completion date: June 2015
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

adult patients with non small cell lung cancer who receive, or are considered for, systemic therapy

Exclusion Criteria:

renal failure pregnancy known contrast allergy

Study Design

Observational Model: Case-Only, Time Perspective: Prospective

Related Conditions & MeSH terms

• Carcinoma, Non-Small-Cell Lung
• Lung Neoplasms
• Non Small Cell Lung Cancer

Locations

Country	Name	City	State
United States	University of California, Davis Medical Center	Sacramento	California

Sponsors (2)

Lead Sponsor	Collaborator
University of California, Davis	Radiological Society of North America

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Yield of conducting CTP studies	Yield is determined as the percentage of assessable CTP studies, relative to all performed studies	2 years	No
Secondary	Variability of CTP measurements	Variability will be determined from two consecutively acquired CTP examinations, and repeated analyses of the same studies	2 years	No
Secondary	Magnitude of treatment induced changes in tumor blood flow	The magnitude of treatment induced changes in blood flow will be determined from comparisons of bloodflow before and after treatment	2 years	No